<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35483593</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1464-3405</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Bioorganic &amp; medicinal chemistry letters</Title>
          <ISOAbbreviation>Bioorg Med Chem Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides.</ArticleTitle>
        <Pagination>
          <StartPage>128761</StartPage>
          <MedlinePgn>128761</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmcl.2022.128761</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0960-894X(22)00237-2</ELocationID>
        <Abstract>
          <AbstractText>Resistance to telithromycin and off-target effects associated with the metabolic instability present serious and challenging problems for the development of novel macrolides. Herein, studies of hybrids of macrolides and quinolones (termed macrolones) bridged with linkers from 11,12-cyclic carbamate of macrolides revealed different structure-activity relationships from the previously reported macrolones bridged with linkers derived from 6-, 9- and 4''-positions of macrolides. The optimized macrolone 34 g with a longer and rigid sidechain than telithromycin had improved metabolic stability compared to telithromycin (t<sub>1/2</sub>: 110 vs 32 min), whose future has been heavily clouded by metabolic issues. Moreover, 34 g was 38-fold more potent than telithromycin against A2058/2059-mutated Mycoplasma pneumoniae (8 vs 315 μM), which may be attributed to a novel mode of action between the carboxylic acid of quinolone moiety and the bacterial ribosome. This work increases the prospect for discovery of novel and safe antibacterial agents to combat serious human infectious diseases.</AbstractText>
          <CopyrightInformation>Copyright © 2022. Published by Elsevier Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xie-Peng</ForeName>
            <Initials>XP</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 102488, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, State Key Laboratory of Infectious Disease Prevention and Control, Beijing 102206, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 102488, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jue-Ru</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 102488, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jian-Zhong</ForeName>
            <Initials>JZ</Initials>
            <AffiliationInfo>
              <Affiliation>National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, State Key Laboratory of Infectious Disease Prevention and Control, Beijing 102206, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Li-Yong</ForeName>
            <Initials>LY</Initials>
            <AffiliationInfo>
              <Affiliation>National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, State Key Laboratory of Infectious Disease Prevention and Control, Beijing 102206, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cushman</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China. Electronic address: liyun19702@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Jian-Hua</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 102488, China; Yangtze Delta Region Academy of Beijing Institute of Technology, Jiaxing 314019, China. Electronic address: ljhbit@bit.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Bioorg Med Chem Lett</MedlineTA>
        <NlmUniqueID>9107377</NlmUniqueID>
        <ISSNLinking>0960-894X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048628">Ketolides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015363">Quinolones</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048628" MajorTopicYN="Y">Ketolides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009177" MajorTopicYN="N">Mycoplasma pneumoniae</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015363" MajorTopicYN="Y">Quinolones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Macrolide</Keyword>
        <Keyword MajorTopicYN="N">Metabolic stability</Keyword>
        <Keyword MajorTopicYN="N">Mycoplasma pneumoniae</Keyword>
        <Keyword MajorTopicYN="N">Quinolone</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>19</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35483593</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bmcl.2022.128761</ArticleId>
        <ArticleId IdType="pii">S0960-894X(22)00237-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
